Among patients on dialysis taking gabapentin, the major adverse events rate (per 100 person-years) ranged from 9.3 for any fracture to 37.8 for altered mental status. Gabapentin treatment, especially ...
GLP-1 drug use is increasing materially in patients with diabetes and obesity, and uncertainty around GLP-1 expansion has added risk to dialysis stocks even as pandemic challenges, including excess ...
Two studies in CJASN offer a better understanding of the effects of COVID-19 vaccination on individuals with kidney failure who are undergoing long-term dialysis. One study compared trends in COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback